Swiss rare diseases focused biotech Therachon today announced the acquisition of Canada-based GLyPharma Therapeutic for an undisclosed amount.
This transformational deal marks Therachon's evolution to a multi-asset rare disease company by adding apraglutide (FE 203799), a next-generation synthetic GLP-2 analog targeting short bowel syndrome (SBS) and other devastating rare gastrointestinal diseases. The transaction comes on the heels of a $60 million mezzanine financing led by Novo Holdings.
According to the latest report published by Credence Research, “ Short Bowel Syndrome Market the market was valued at $315.1 million in 2016, and is expected to reach $ 2.9 billion by 2025, expanding at a compound annual growth rate (CAGR) of 27.5% from 2017 to 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze